Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

Published on January 24, 2022

Investors are likely to focus on Vertex Pharmaceuticals' (VRTX) CF product revenues, especially sales of its triple combo CF drug Trikafta/Kaftrio, and non-CF pipeline progress.

Continue reading on website
Other news

Should You Buy the Dip in Netflix?

January 24, 2022
Streaming giant Netflix (NFLX) remains among the top entertainment streaming platforms worldwide. However, its stock dipped nearly 21% in price last week after the company reported its fiscal fourth-quarter earnings...

Avnet (AVT) to Report Q2 Earnings: What's in the Offing?

January 24, 2022
Avne's (AVT) Q2 top-line results are likely to have benefited from solid demand for its electronic components, while its cost-reduction programs are anticipated to have boosted the bottom line.